209,824 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 209,824 shares of the biopharmaceutical company's stock, valued at approximately $10,032,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.17% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter valued at $29,000. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HALO shares. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target on the stock. in a research note on Tuesday, May 13th. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Price Performance

NASDAQ:HALO traded up $0.54 during trading hours on Wednesday, reaching $53.85. 1,369,673 shares of the company were exchanged, compared to its average volume of 1,647,775. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51. The company has a market capitalization of $6.64 billion, a P/E ratio of 15.70, a P/E/G ratio of 0.42 and a beta of 1.26. The business has a 50 day moving average of $58.32 and a 200 day moving average of $55.70.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.